Compare Oxford Lane Capital Corp (OXLC) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs Stryker Corporation — how do they compare? Oxford Lane Capital Corp trades at $8.56 (market cap $835.71M), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 127.1× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (28.15%). Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 50 Days and Stryker Corporation for 21 Days on average.
| OXLC | SYK | |
|---|---|---|
Market Cap | $835.71M | $106.24B |
Volume | 1,125,263 | 2,982,001 |
Sector | Financials | Health |
52-Week High | $16.66 | $388.35 |
52-Week Low | $8.15 | $269.75 |
Typical Hold Time | 50 Days | 21 Days |
Enterprise Value | $1.23B | $117.70B |
Dividend Yield | 28.15% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.53, up 0.83% today, but faces significant fundamental challenges with a negative ROE of -39.16% and recent earnings misses. Technical indicators show a bearish trend with strong selling pressure on moving averages, though RSI suggests potential oversold conditions. The company maintains a consistent $0.20 monthly dividend while navigating substantial net asset value declines reported in recent updates.
The outlook remains cautious with deteriorating fundamentals offset by high dividend yield. Key risks include unsustainable payout ratios and NAV erosion, while potential upside exists if CLO market conditions stabilize. Analyst sentiment is divided with 50% buy ratings but technicals indicate continued downward pressure.
Stryker (SYK) trades at $276.97, up 0.57% today, amid a bearish technical signal with key support at $274 and resistance at $279. The company reported strong profitability with a 14.43% net income margin and beat Q2 2026 EPS estimates, though it missed in Q1. Recent news highlights ongoing legal scrutiny related to manufacturing issues disclosed in September 2026, which caused a significant share price drop.
Analyst consensus remains strongly bullish with a $368.11 price target, but risks include persistent manufacturing problems and potential securities litigation. Earnings growth and margin expansion support the long-term outlook, though near-term volatility may persist pending Q3 2026 results on October 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
